QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
QQQ   354.50 (+0.38%)
AAPL   180.96 (+0.22%)
MSFT   326.79 (+0.47%)
META   264.95 (+0.14%)
GOOGL   122.23 (+0.07%)
AMZN   123.43 (-0.66%)
TSLA   244.40 (+4.06%)
NVDA   387.70 (+0.68%)
NIO   7.74 (-0.64%)
BABA   85.50 (-0.74%)
AMD   124.92 (+3.20%)
T   15.96 (-0.75%)
F   13.74 (+1.18%)
MU   65.43 (+0.17%)
CGC   0.68 (-1.45%)
GE   106.30 (+0.22%)
DIS   91.95 (-0.63%)
AMC   4.77 (+1.92%)
PFE   38.97 (-0.31%)
PYPL   63.49 (-1.17%)
NFLX   420.02 (+2.60%)
NASDAQ:VXRT

Vaxart (VXRT) Stock Forecast, Price & News

$0.85
-0.05 (-5.57%)
(As of 06/9/2023 ET)
Compare
Today's Range
$0.83
$0.91
50-Day Range
$0.60
$1.41
52-Week Range
$0.56
$4.62
Volume
4.05 million shs
Average Volume
1.77 million shs
Market Capitalization
$115.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.75

Vaxart MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
460.0% Upside
$4.75 Price Target
Short Interest
Bearish
13.80% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.32mentions of Vaxart in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.70) to ($0.65) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.63 out of 5 stars

Medical Sector

841st out of 986 stocks

Biological Products, Except Diagnostic Industry

136th out of 161 stocks


VXRT stock logo

About Vaxart (NASDAQ:VXRT) Stock

Vaxart, Inc. operates as a clinical-stage biotechnology company, which engages in the development of oral recombinant vaccines based on its Vector-Adjuvant-Antigen Standardized Technology oral vaccine platform. Its investigational vaccines are administered using a room temperature-stable tablet, rather than by injection. It is developing prophylactic vaccine candidates that target a range of infectious diseases, including SARS-CoV-2, norovirus, seasonal influenza and respiratory syncytial virus (RSV). The company was founded in 2004 and is headquartered in South San Francisco, CA.

Receive VXRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter.

VXRT Stock News Headlines

Vaxart Shares Sink 27% on Offering Pricing
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
Why Is Vaxart (VXRT) Stock Down 25% Today?
Unlock Profit Potential: Find Hidden Trade Opportunities Using A.I.
There’s a tool that scans and picks the best stocks…how you approach the trades is up to you. But when you’re forecasting 1 – 3 days in advance, it’s not really a guessing game. Stop guessing and start predicting to add consistency to your trades… no matter what happens in the market.
Vaxart Names Phillip Lee as Chief Financial Officer
See More Headlines

VXRT Price History

VXRT Company Calendar

Last Earnings
3/15/2023
Today
6/09/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VXRT
Previous Symbol
NASDAQ:NABI
Employees
110
Year Founded
2004

Price Target and Rating

Average Stock Price Forecast
$4.75
High Stock Price Forecast
$8.00
Low Stock Price Forecast
$1.50
Forecasted Upside/Downside
+462.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-107,760,000.00
Pretax Margin
-15,454.95%

Debt

Sales & Book Value

Annual Sales
$697,000.00
Book Value
$0.84 per share

Miscellaneous

Free Float
131,529,000
Market Cap
$114.44 million
Optionable
Not Optionable
Beta
0.78

Social Links


Key Executives

  • Andrei Floroiu
    President, Chief Executive Officer & Director
  • Phillip Eric Lee
    Chief Financial Officer
  • Sean N. TuckerSean N. Tucker
    Chief Scientific Officer & Senior Vice President
  • James F. Cummings
    Chief Medical Officer
  • Raymond D. Stapleton
    Chief Technology Officer













VXRT Stock - Frequently Asked Questions

Should I buy or sell Vaxart stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VXRT shares.
View VXRT analyst ratings
or view top-rated stocks.

What is Vaxart's stock price forecast for 2023?

3 Wall Street research analysts have issued 12-month price objectives for Vaxart's shares. Their VXRT share price forecasts range from $1.50 to $8.00. On average, they expect the company's stock price to reach $4.75 in the next year. This suggests a possible upside of 462.8% from the stock's current price.
View analysts price targets for VXRT
or view top-rated stocks among Wall Street analysts.

How have VXRT shares performed in 2023?

Vaxart's stock was trading at $0.9609 at the beginning of 2023. Since then, VXRT stock has decreased by 12.2% and is now trading at $0.8440.
View the best growth stocks for 2023 here
.

When is Vaxart's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our VXRT earnings forecast
.

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) issued its quarterly earnings data on Wednesday, March, 15th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.22) by $0.04. The biotechnology company had revenue of $0.02 million for the quarter, compared to analyst estimates of $0.15 million.

What ETFs hold Vaxart's stock?

ETFs with the largest weight of Vaxart (NASDAQ:VXRT) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS).ETFMG Treatments Testing and Advancements ETF (GERM).

When did Vaxart's stock split?

Vaxart shares reverse split before market open on Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

What other stocks do shareholders of Vaxart own?
What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Who are Vaxart's major shareholders?

Vaxart's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.50%), Geode Capital Management LLC (1.96%), State Street Corp (1.96%), Two Sigma Investments LP (0.88%), Two Sigma Advisers LP (0.81%) and Charles Schwab Investment Management Inc. (0.73%). Insiders that own company stock include Armistice Capital, Llc, Fuad Ahmad, Margaret Echerd, Robert A Yedid, Sean Tucker, W Mark Watson and Wouter Latour.
View institutional ownership trends
.

How do I buy shares of Vaxart?

Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $0.84.

How much money does Vaxart make?

Vaxart (NASDAQ:VXRT) has a market capitalization of $114.44 million and generates $697,000.00 in revenue each year. The biotechnology company earns $-107,760,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

How many employees does Vaxart have?

The company employs 110 workers across the globe.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The official website for the company is www.vaxart.com. The biotechnology company can be reached via phone at (650) 550-3500, via email at ir@vaxart.com, or via fax at 650-871-8580.

This page (NASDAQ:VXRT) was last updated on 6/9/2023 by MarketBeat.com Staff

My Account -